Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Novartis Trial Shows Benefit in Patients with Breast Cancer
Novartis today announced positive topline results from an interim analysis of NATALEE, a Phase III […]
Dawn Health partners with leading Pharmaceutical Company, Novartis, to Transform Chronic Care
Dawn Health, a global leader in digital health, has announced a strategic partnership with Novartis, […]
Novartis Pharmaceuticals UK Launches World-first Health-tech Investor Partnership to Reimagine Cardiovascular Care
Novartis Pharmaceuticals UK announces the launch of the Novartis Biome UK Heart Health Catalyst 2022, […]
New Phase III Data Show Novartis Tislelizumab Significantly Extended Median Overall Survival by More Than 6 Months in First-line Advanced Esophageal Cancer in Combination With Chemotherapy
Today Novartis announced results from the Phase III RATIONALE 306 trial showing tislelizumab plus chemotherapy […]
Novartis Receives GB Licence for Scemblix®▼ (Asciminib), the First STAMP Inhibitor for Patients With Chronic Myeloid Leukaemia
Novartis UK has announced that Scemblix® (asciminib) has been granted Marketing Authorisation in Great Britain by […]
New Novartis Data Demonstrate Only Kisqali® Offers More Life in the First-line Setting for Postmenopausal HR+/HER2- Advanced Breast Cancer Patients
Novartis today announced updated median overall survival (OS) results for Kisqali® (ribociclib) in combination with fulvestrant […]
Novartis Tislelizumab plus Chemotherapy Significantly Improved Overall Survival as First-line Treatment for Advanced Esophageal Cancer in Phase III Study
Novartis today announced positive topline results from an interim analysis of the Phase III RATIONALE […]
Novartis Pluvicto™ Approved by FDA as First Targeted Radioligand Therapy for Treatment of Progressive, PSMA-positive Metastatic Castration-resistant Prostate Cancer
Novartis announced today that the US Food and Drug Administration (FDA) approved Pluvicto™ (lutetium Lu […]
Novartis to Acquire Gyroscope Therapeutics, Adding a One-time Gene Therapy That Could Transform Care for Geographic Atrophy, a Leading Cause of Blindness
Novartis announced today that it entered into a definitive agreement to acquire all of the […]
Novartis Launches Virtual Innovation Hub to Accelerate Digital Health Solutions in Sub-Saharan Africa
Novartis has announced the launch of its new innovation hub, Novartis Biome sub-Saharan Africa (SSA), […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more